Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
25.51
-3.14 (-10.96%)
At close: Apr 10, 2026, 4:00 PM EDT
25.80
+0.29 (1.14%)
After-hours: Apr 10, 2026, 7:21 PM EDT
Evommune Revenue
In the year 2025, Evommune had annual revenue of $13.00M with 85.71% growth.
Revenue (ttm)
$13.00M
Revenue Growth
+85.71%
P/S Ratio
70.68
Revenue / Employee
$270,833
Employees
48
Market Cap
918.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.00M | 6.00M | 85.71% |
| Dec 31, 2024 | 7.00M | 2.00M | 40.00% |
| Dec 31, 2023 | 5.00M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEVMN News
- 6 days ago - Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine - Business Wire
- 5 weeks ago - Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - Business Wire
- 2 months ago - Evommune Announces $125 Million Private Placement - Business Wire
- 2 months ago - Evommune Stock Cools Off After Big Rally On Successful Eczema Trial - Benzinga
- 2 months ago - Evommune's Stock Surges On Strong Results For New Eczema Drug - Benzinga
- 2 months ago - Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis - Business Wire
- 4 months ago - Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 5 months ago - Evommune Announces Pricing of its Initial Public Offering - PRNewsWire